Aardvark Therapeutics (AARD) Retained Earnings (2025 - 2026)
Aardvark Therapeutics (AARD) reported Retained Earnings of -$137.5 million for Q1 2026, down 312613.64% on a YoY basis from N/an in Q1 2025, and down 169860.49% sequentially from $81000.0 in Q4 2025.
Aardvark Therapeutics (AARD) Retained Earnings (2025 - 2026) Analysis & Trends
Aardvark Therapeutics (AARD) has 2 years of Retained Earnings data on file, last reported at -$137.5 million in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings fell 312613.64% year-over-year to -$137.5 million; the trailing twelve-month figure through Mar 2026 stood at -$137.5 million (down 312613.64% YoY), and the FY2025 full-year result was $81000.0, changed N/A from the prior year.
- Retained Earnings fell to -$137.5 million in Q1 2026, from $81000.0 in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $82000.0 in Q3 2025 to a low of -$137.5 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | Aardvark Therapeutics | 139.40 Mn | 19.44 Mn | - | -137.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -137.51 Mn |
| Dec 31, 2025 | 81,000.00 |
| Sep 30, 2025 | 82,000.00 |
| Jun 30, 2025 | -3,000.00 |
| Mar 31, 2025 | 44,000.00 |